Cut price Kymriah? ThermoGenesis thinks so with automated CAR-T tech – BioPharma-Reporter.com
BioPharma-Reporter.com |
Cut price Kymriah? ThermoGenesis thinks so with automated CAR–T tech
BioPharma-Reporter.com In August, Novartis made history when its product Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR) T-cell therapy to win US approval. The product is made by collecting a patient's cells through apheresis at a specialised … |
